Slimming World has updated its membership rules to allow people using GLP‑1 weight‑loss medications to be eligible for its award schemes and competitions, the organisation has confirmed. The change, now in force, applies across Slimming World’s community network in the UK and Ireland.
What has changed
Under the revised rules, members who use drugs such as Wegovy and Mounjaro will be able to be nominated for the charity’s high‑profile recognition prizes, including Slimmer of the Week and Slimmer of the Month, as well as to enter member competitions that previously excluded people on these treatments.
The organisation said the move was prompted by the rising use of glucagon‑like peptide‑1 (GLP‑1) receptor agonist medications among people attending its groups and by a review of its own data and member feedback. Slimming World supports members through around 12,000 community groups across the UK and Ireland as well as through a digital service.
“We now know that members who engage with Slimming World's programme and attend group regularly achieve excellent results, whether they're using weight loss medication or not,”
The line above is from Slimming World’s managing director, who said the organisation updated awards and competitions "to include members who’ve used or are using weight loss medication." The aim, the group added, is that every member should feel “welcomed, supported and fully included”.
Why the change matters
GLP‑1 medications, originally developed for diabetes care, have in recent years become widely used off‑label or under new licences to treat obesity. Their increasing prevalence has prompted debate around fairness in community weight‑loss settings and raised questions about how group programmes should recognise progress when pharmacological support is involved.
Slimming World’s decision addresses those concerns by removing explicit barriers to participation in awards. It also reflects the charity’s own analysis, which it says shows that members who combine the organisation’s behavioural and dietary programme with medical treatment still attain strong outcomes if they engage consistently with the service.
The organisation emphasised inclusion, saying members using medicines alongside the food optimising plan should be treated the same as others when being measured for awards and competitions.
Practical effects for members
- Eligibility: Users of GLP‑1 medications are now eligible for Slimmer of the Week and Slimmer of the Month awards.
- Competitions: Member competitions, which consider broader criteria beyond weight loss, will accept entries from people who have used or are using these medicines.
- Support model: The policy change formalises the idea that behavioural support in group settings remains valuable, regardless of pharmacological assistance.
| Item | Detail |
|---|---|
| Community groups | ~12,000 across UK & Ireland |
| Medications named | Wegovy, Mounjaro (GLP‑1 class) |
| Key awards affected | Slimmer of the Week, Slimmer of the Month, member competitions |
The organisation said the rule update follows a period in which understanding of how these therapies interact with behaviour change programmes has grown. It drew on its members’ experiences and feedback from local consultants in deciding to change the eligibility criteria.
Questions and wider context
While the rule change deals with internal recognition, it also sits against a backdrop of wider discussion in the health sector about the role of GLP‑1 drugs in public health. These medicines have been credited with substantial weight reductions in clinical trials and real‑world prescribing has expanded rapidly. At the same time, health‑care professionals and patient groups have debated access, long‑term effects and how to combine medication with lifestyle and community support.
Slimming World’s move is unlikely to settle those broader debates but it does formalise one practical response from a major provider of community weight‑loss support: treat members uniformly and recognise commitment and outcomes irrespective of adjunct medical treatment. The organisation said it wants every member to feel "welcomed, supported and fully included" as the use of GLP‑1 therapies grows.
It remains to be seen how other similar community programmes will respond and whether this change prompts further discussion about standards of assessment and recognition where medication plays a part in people’s weight‑loss journeys.
